2-氨基-2,2-二环丙基乙酸 | 6321-21-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-2,2-二环丙基乙酸
• 英文名称: dicyclopropylglycine
• 英文别名: amino(dicyclopropyl)acetic acid；2-amino-2,2-dicyclopropylacetic acid；2-Azaniumyl-2,2-dicyclopropylacetate
• CAS: 6321-21-7
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: XURKQOZJWNQCDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  4-(二氟甲氧基)苯基异氰酸酯 、 2-氨基-2,2-二环丙基乙酸 在 sodium hydroxide 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以68%的产率得到dicyclopropyl({[4-(difluoromethoxy)phenyl]carbamoyl}amino)acetic acid
  参考文献：
  名称：

  EP3524240

  摘要：

  公开号：

文献信息

• X=Y-ZH Systems as potential 1.3-dipoles. part 16. cyclopropyl substituted azomethine ylides as mechanistic probes in 1.3-dipolar cycloaddition reactions
  作者：Ronald Grigg、P.Armstrong William

  DOI：10.1016/s0040-4020(01)85931-7

  日期：1988.1

  the 1,2-prototropic route and the decarboxylative route to azomethine ylides were studied with cyclopropyl substituents located on one or both carbon atoms of the azomethine ylides and in several instances in the dipolarophile. Cycloadducts were obtained in good yield with no evidence of biradical intermediates, i.e. no products arising from cyclopropyl radical ⇀ but-3-enyl radical rearrangements were

  用位于偶氮甲胺基团的一个或两个碳原子上的环丙基取代基和在偶极亲子基团中的几种情况下，研究了涉及1,2-质子化途径和脱羧途径的环加成反应。未获得双自由基中间体的证据，即获得了高收率的环戊二烯，即未检测到由环丙基自由基⇀But-3-enyl自由基重排产生的产物。
• [EN] PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE<br/>[FR] PROMÉDICAMENTS D'ANALOGUES NUCLÉOTIDIQUES DE PHOSPHONAMIDE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：GILEAD SCIENCES INC

  公开号：WO2022031894A1

  公开（公告）日：2022-02-10

  Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.

  揭示了用于治疗病毒感染的化合物、组合物和方法，例如人类免疫缺陷病毒（HIV）和/或乙型肝炎病毒（HBV）感染。具体来说，揭示了磷酰胺核苷类似物的前药和其制备和用作治疗或预防剂的方法。
• [EN] NOVEL ARYL-CYANOGUANIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS D'ARYL-CYANOGUANIDINE
  申请人：BAYER PHARMA AG

  公开号：WO2016166186A1

  公开（公告）日：2016-10-20

  The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.

  本发明涉及蛋白酰赖氨酸N-甲基转移酶SMYD2（SET和MYND结构域含有蛋白2）抑制剂，特别是通式（I）的SMYD2抑制剂取代氰基胍-吡唑啉，其中R1，R2，R3，R4和R5具有如下所述和定义的含义，以及包含根据本发明的化合物的制药组合物以及它们在高增殖性疾病，特别是癌症，以及肿瘤性疾病的预防和治疗中的预防和治疗用途。本发明还涉及SMYD2抑制剂用于良性增生，动脉粥样硬化性疾病，败血症，自身免疫性疾病，血管疾病，病毒感染，神经退行性疾病，炎症性疾病，动脉粥样硬化性疾病和男性生育控制。
• Achiral amino acid acyl esters of ganciclovir and its derivatives
  申请人：Syntex (USA) Inc.

  公开号：US05543414A1

  公开（公告）日：1996-08-06

  Compounds of the Formula I ##STR1## wherein X is hydrogen, chloro, amino or hydroxy; R.sup.1 is an achiral amino acid acyl residue with a tertiary .alpha.-carbon atom. Preferred achiral amino acid acyl residues have the formula ##STR2## wherein each R.sup.2 is alkyl with 1 to 6 carbon atoms, cycloalkyl with 3 to 5 carbon atoms, or benzyl; or the two R.sup.2 groups link together to form a polymethylene group with 3 to 9 carbon atoms, and pharmaceutically acceptable salts thereof are antiviral agents with improved absorption. Intermediates for the preparation of the compounds of Formula I are also described.

  化合物I的公式为##STR1## 其中X为氢、氯、氨基或羟基；R.sup.1是带有三级α-碳原子的非手性氨基酸酰基残基。优选的非手性氨基酸酰基残基具有以下公式##STR2## 其中每个R.sup.2为1至6个碳原子的烷基、3至5个碳原子的环烷基或苄基；或两个R.sup.2基团连接在一起形成具有3至9个碳原子的聚亚甲基基团，以及其药学上可接受的盐是具有改善吸收的抗病毒剂。还描述了制备化合物I的中间体。
• UREA DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3524240A1

  公开（公告）日：2019-08-14

  An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.

  本发明的目的是找到一种新型药物，它具有极佳的色氨酸酶抑制作用，并通过减少血液中吲哚硫酸酯的产生来抑制肾功能恶化，从而保护肾脏。本发明提供了一种药物组合物，其活性成分含有下式所代表的化合物或其药理学上可接受的盐： 其中 R1 和 R2 相同或不同，代表 C1-C6 烷基或类似物，Ar 代表任选取代的苯基或任选取代的噻吩基。